The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

The 2024–25 season saw several American players lift trophies in 2025, and the foursome of Ricardo Pepi, Sergiño Dest, Malik ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

As we celebrate the festive season, what better gift than a rerank of the best, most in-form teams across Europe's top five ...

Bayer Aktiengesellschaft remains deeply undervalued despite ongoing operational and litigation headwinds, supporting a bullish stance. Q3/25 results were weak, but technicals and intrinsic value ...

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science ...

Bayer Leverkusen moved up to second in the Bundesliga after a ruthless first-half showing saw them down Wolfsburg 3-1 at Volkswagen Arena on Saturday. Kasper Hjulmand’s side netted three times in the ...

The Food and Drug Administration (FDA) on Wednesday granted accelerated approval to Bayer AG‘s (OTC: BAYRY) Hyrnuo (sevabertinib) for adults with a specific type of advanced lung cancer. The approval ...

Bayer AG BAYRY reported third-quarter 2025 core earnings of 17 cents per American Depositary Receipt (ADR), which comfortably beat the Zacks Consensus Estimate of 13 cents per ADR. The company ...

Litigation costs seen impacting 2025 reported earnings CEO has said aims to resolve most glyphosate cases by 2026 Bayer has cut 13,500 jobs to speed up decision making FRANKFURT, Nov 12 (Reuters) - ...